Profile
Sector:
HealthcareCountry:
United StatesIPO:
25 September 2008Website:
http://aytubio.comNext earnings report:
30 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 7 min agoDividend
Analysts recommendations
Institutional Ownership
AYTU Latest News
Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q1 2024 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Robert Blum - IR Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants Naz Rahman - Maxim Group Robert Blum Good afternoon, everyone, and thank you for joining us for Aytu BioPharma's Fiscal 2024 First Quarter Financial Results Conference Call for the period ended September 30, 2023. Joining us on today's call is Aytu's CEO, Josh Disbrow, and the company's Chief Financial Officer, Mark Oki.
What do you consider the best penny stocks? Are they the ones exploding higher within a single session?
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q4 2023 Earnings Call Transcript September 27, 2023 4:30 PM ET Company Participants Robert Blum - IR Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants Naz Rahman - Maxim Group Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q4 Earnings Conference Call.
ENGLEWOOD, CO / ACCESSWIRE / September 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its fourth quarter and fiscal year ended June 30, 2023, after the market close on Wednesday, September 27, 2023. The Company has scheduled a conference call that same day, Wednesday, September 27, 2023, at 4:30 pm ET, to review the results.
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q3 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Roger Weiss - Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Naz Rahman - Maxim Group, LLC Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q3 Results Conference Call.
What type of business is Aytu BioPharma?
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
What sector is Aytu BioPharma in?
Aytu BioPharma is in the Healthcare sector
What industry is Aytu BioPharma in?
Aytu BioPharma is in the Drug Manufacturers - Specialty & Generic industry
What country is Aytu BioPharma from?
Aytu BioPharma is headquartered in United States
When did Aytu BioPharma go public?
Aytu BioPharma initial public offering (IPO) was on 25 September 2008
What is Aytu BioPharma website?
https://aytubio.com
Is Aytu BioPharma in the S&P 500?
No, Aytu BioPharma is not included in the S&P 500 index
Is Aytu BioPharma in the NASDAQ 100?
No, Aytu BioPharma is not included in the NASDAQ 100 index
Is Aytu BioPharma in the Dow Jones?
No, Aytu BioPharma is not included in the Dow Jones index
When does Aytu BioPharma report earnings?
The next expected earnings date for Aytu BioPharma is 30 August 2024